Infliximab-induced hypoglycemia, a rare but relevant side effect

Rev Esp Enferm Dig. 2022 Jun;114(6):364-365. doi: 10.17235/reed.2022.8460/2021.

Abstract

Tumor necrosis factor (TNF) inhibitors are part of the therapeutic arsenal for many immune-mediated diseases and, especially in inflammatory bowel disease (IBD), have led to a change in the management of this disease.

Publication types

  • Letter

MeSH terms

  • Adalimumab / therapeutic use
  • Humans
  • Hypoglycemia* / chemically induced
  • Hypoglycemia* / drug therapy
  • Inflammatory Bowel Diseases* / drug therapy
  • Infliximab / adverse effects
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha

Substances

  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab